This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Schrödinger CEO Ramy Farid wants you to know that his company isn’t an AI company…but he’ll call it that if you want to. The company, founded in 1990, started out by making software that used the basic laws of physics to laboriously and exactly predict how molecules will interact with each other in space. Those calculations, rooted in the field of computational physics, needed lots of expensive and time-consuming computing power to run, and many people abandoned those t
A collection of hospitals in Rochester, New York, have teamed up to create better access to prescription drugs and combat the city’s pharmacy desert issue.
WASHINGTON — People close to Robert F. Kennedy Jr. are exploring a proposal that could upend how physician payment is determined in America, four sources familiar with the process told STAT.
Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Table of Contents Sr# Headings 1 Introduction 2 What Is Display Advertising? 3 Why Display Advertising Matters in Pharma 4 Key Benefits of Display Advertising 5 Targeting: Reaching the Right Audience 6 Personalization in Display Ads 7 Case Study: Successful Pharma Display Campaigns 8 Choosing the Right Platforms 9 Metrics to Track for ROI Success 10 Regulatory Challenges and Solutions 11 The Role of Branded Drugs in Display Ads 12 Creative Best Practices for Display Ads 13 Aligning Display Ads w
In 2016, the Arkansas Legal Aid Center was flooded with calls. People on a Medicaid program that provided in-home care assistance were having their caregiving hours cut. Reducing the hours for somebody with quadriplegia or cerebral palsy was devastating, said Kevin De Liban, an attorney with the organization at the time. “People are lying in their own waste, people are getting bed sores from not being turned.
134
134
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
In 2016, the Arkansas Legal Aid Center was flooded with calls. People on a Medicaid program that provided in-home care assistance were having their caregiving hours cut. Reducing the hours for somebody with quadriplegia or cerebral palsy was devastating, said Kevin De Liban, an attorney with the organization at the time. “People are lying in their own waste, people are getting bed sores from not being turned.
Three research posters presented at the American Heart Association’s 2024 Scientific Sessions looked into the use of SGLT-2 inhibitors in patients with type 2 diabetes and cardiovascular complications.
Kura Oncology has signed a global partnership with the Japanese drugmaker Kyowa Kirin to develop and sell Kura’s experimental treatment for acute leukemia, the companies said Wednesday. Kyowa is paying $320 million to Kura in exchange for global licensing rights to the drug, called ziftomenib, which is in a late-stage clinical trial for a genetically defined type of advanced leukemia.
Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. | The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics.
Pfizer said its chief oncology officer, Chris Boshoff, will head all of the company’s research and development efforts in addition to keeping his current duties overseeing the company’s scientific and commercial efforts in cancer. Boshoff replaces Mikael Dolsten, who led research and development at the drug giant for 15 years and who announced his plans to retire in July.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The country’s largest pharmacy benefit managers and group purchasing organizations are going on offense against the Federal Trade Commission (FTC). | Major PBMs are countersuing the Federal Trade Commission, claiming the agency is biased and has too much authority to upend the industry.
As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety findings” linked to the British drugmaker’s bleeding reversal agent.
When Randi Johnson was undergoing treatment for breast cancer, her husband, Brian, often felt at a loss to help. But then, when he and Randi met with a surgeon to discuss reconstructing her breast, he was struck by something he could do. The Midwestern father of five, a lifelong tinkerer, decided to make his wife the best possible prosthetic nipple.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Johnson & Johnson and Merck are laying off workers in Chi | Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from Chinese news outlets.
Streamline claims management in the healthcare industry by eliminating swivel chair processes. Learn how healthcare providers and biopharma companies can optimise efficiency.
A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu | A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star ADC Enhertu.
Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference. Stay updated on the latest advancements in oncology.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we meet Pfizer’s new chief scientific officer, ponder why the stock for Silence Therapeutics dropped despite promising data, and see that pharma executives aren’t too worried about Robert F.
The European Medicines Agency (EMA) has implemented a strategy to accelerate drug approvals in the EU. Learn more about their initiatives and how they are streamlining the process for faster access to medicines.
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not particularly appealing. And what better way to make the time fly than to keep busy.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) sold over-the-counter (OTC) without a prescription, often under brand names such as Motrin or Advil. It’s designed to treat fevers and pain associated with common problems like headaches, muscle pain, toothaches, and menstrual cramps, but it goes one step further than pain relievers such as acetaminophen by helping reduce the inflammation that’s causing your pain.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
142 
Let's personalize your content